Historical Valuation
Zevra Therapeutics Inc (ZVRA) is now in the Fair zone, suggesting that its current forward PS ratio of 3.51 is considered Fairly compared with the five-year average of -4.89. The fair price of Zevra Therapeutics Inc (ZVRA) is between 7.47 to 36.70 according to relative valuation methord.
Relative Value
Fair Zone
7.47-36.70
Current Price：8.69
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Zevra Therapeutics Inc (ZVRA) has a current Price-to-Book (P/B) ratio of 3.52. Compared to its 3-year average P/B ratio of 5.21 , the current P/B ratio is approximately -32.42% higher. Relative to its 5-year average P/B ratio of 3.88, the current P/B ratio is about -9.22% higher. Zevra Therapeutics Inc (ZVRA) has a Forward Free Cash Flow (FCF) yield of approximately -5.16%. Compared to its 3-year average FCF yield of -13.32%, the current FCF yield is approximately -61.26% lower. Relative to its 5-year average FCF yield of -7.94% , the current FCF yield is about -35.02% lower.
P/B
Median3y
5.21
Median5y
3.88
FCF Yield
Median3y
-13.32
Median5y
-7.94
Competitors Valuation Multiple
AI Analysis for ZVRA
The average P/S ratio for ZVRA competitors is 5.23, providing a benchmark for relative valuation. Zevra Therapeutics Inc Corp (ZVRA.O) exhibits a P/S ratio of 3.51, which is -32.98% above the industry average. Given its robust revenue growth of 605.36%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ZVRA
1Y
3Y
5Y
Market capitalization of ZVRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ZVRA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ZVRA currently overvalued or undervalued?
Zevra Therapeutics Inc (ZVRA) is now in the Fair zone, suggesting that its current forward PS ratio of 3.51 is considered Fairly compared with the five-year average of -4.89. The fair price of Zevra Therapeutics Inc (ZVRA) is between 7.47 to 36.70 according to relative valuation methord.
What is Zevra Therapeutics Inc (ZVRA) fair value?
ZVRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Zevra Therapeutics Inc (ZVRA) is between 7.47 to 36.70 according to relative valuation methord.
How does ZVRA's valuation metrics compare to the industry average?
The average P/S ratio for ZVRA's competitors is 5.23, providing a benchmark for relative valuation. Zevra Therapeutics Inc Corp (ZVRA) exhibits a P/S ratio of 3.51, which is -32.98% above the industry average. Given its robust revenue growth of 605.36%, this premium appears sustainable.
What is the current P/B ratio for Zevra Therapeutics Inc (ZVRA) as of Jan 10 2026?
As of Jan 10 2026, Zevra Therapeutics Inc (ZVRA) has a P/B ratio of 3.52. This indicates that the market values ZVRA at 3.52 times its book value.
What is the current FCF Yield for Zevra Therapeutics Inc (ZVRA) as of Jan 10 2026?
As of Jan 10 2026, Zevra Therapeutics Inc (ZVRA) has a FCF Yield of -5.16%. This means that for every dollar of Zevra Therapeutics Inc’s market capitalization, the company generates -5.16 cents in free cash flow.
What is the current Forward P/E ratio for Zevra Therapeutics Inc (ZVRA) as of Jan 10 2026?
As of Jan 10 2026, Zevra Therapeutics Inc (ZVRA) has a Forward P/E ratio of 17.82. This means the market is willing to pay $17.82 for every dollar of Zevra Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Zevra Therapeutics Inc (ZVRA) as of Jan 10 2026?
As of Jan 10 2026, Zevra Therapeutics Inc (ZVRA) has a Forward P/S ratio of 3.51. This means the market is valuing ZVRA at $3.51 for every dollar of expected revenue over the next 12 months.